Pfizer releases positive new data on Trumenba

US pharma giant Pfizer (NYSE:PFE) has released positive results of two Phase III studies demonstrating the immunogenicity of Trumenba (meningococcal Group B vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the USA and Europe.

The two studies, one in adolescents and one in young adults, met all primary immunogenicity endpoints. Also, secondary data presented show that Trumenba demonstrated similar immune responses against 10 additional MnB strains, in both adolescents and young adults. The data, which continue to support the vaccine’s current safety and tolerability profile, were presented at the 34th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID 2016).

“Trumenba is designed to provide protection against serogroup B meningococcal disease,” said Kathrin Jansen, senior vice president and head of Vaccine Research and Development for Pfizer, adding: “The Phase III data show that Trumenba elicits an immune response that is effective against prevalent meningococcal serogroup B strains in the USA and Europe, as well as 10 additional strains of this unpredictable disease. These data support the expectation that vaccination with Trumenba will help prevent this uncommon, but devastating disease in adolescents and young adults.”